Individualized Approaches and Challenges in Myelofibrosis
Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment. He also explains how treatment decisions are individualized for patients with myeloproliferative neoplasms, including myelofibrosis.
Rampal presented on this topic and more at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.
In addition, Rampal discusses some of the unmet needs that exist in this space, including the need for disease-modifying therapy in this interview with Targeted OncologyTM.
Transcription:
0:09 | We are not really doing gene editing therapy. What we are doing is trying to target some of the other mutations. An example of this is patients who have a concurrent IDH mutation where there has now been data to combine a JAK inhibitor and IDH inhibitor in those types of patients.
0:26 | That is something where we have to get a little better. There is a genetic part of it, where we need to kind of figure out if there is a way to leverage other mutations, like I just mentioned. That is 1 option. The other option is trying to understand, are there particular patient profiles that are going to be more responsive to certain therapies? We are not there yet. I do not think we know the answer to that, but I think that is where we need to go.
0:48 | We need disease-modifying therapy. We need therapies that prevent people from progressing to bone marrow failure or to acute leukemia, and I do not think that we are there yet, or at least we need more data to substantiate whether that is going to happen. So more to come.
